Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.
School of Medical Sciences, Örebro University, Örebro, Sweden.
J Eur Acad Dermatol Venereol. 2024 Jul;38(7):1329-1346. doi: 10.1111/jdv.19908. Epub 2024 Feb 23.
Use of medical devices (MDs), that is, glucose sensors and insulin pumps, in patients with Type 1 diabetes mellitus (T1D) has proven an enormous advantage for disease control. Adverse skin reactions from these MDs may however hamper compliance. The objective of this study was to systematically review and analyse studies assessing the prevalence and incidence of dermatitis, including allergic contact dermatitis (ACD) related to MDs used in patients with T1D and to compare referral routes and the clinical investigation routines between clinics being part of the European Environmental and Contact Dermatitis Research Group (EECDRG). A systematic search of PubMed, EMBASE, CINAHL and Cochrane databases of full-text studies reporting incidence and prevalence of dermatitis in persons with T1D using MDs was conducted until December 2021. The Newcastle-Ottawa Scale was used to assess study quality. The inventory performed at EECRDG clinics focused on referral routes, patient numbers and the diagnostic process. Among the 3145 screened abstracts, 39 studies fulfilled the inclusion criteria. Sixteen studies included data on children only, 14 studies were on adults and nine studies reported data on both children and adults. Participants were exposed to a broad range of devices. Skin reactions were rarely specified. It was found that both the diagnostic process and referral routes differ in different centres. Further data on the prevalence of skin reactions related to MDs in individuals with T1D is needed and particularly studies where the skin reactions are correctly diagnosed. A correct diagnosis is delayed or hampered by the fact that, at present, the actual substances within the MDs are not declared, are changed without notice and the commercially available test materials are not adequately updated. Within Europe, routines for referral should be made more standardized to improve the diagnostic procedure when investigating patients with possible ACD from MDs.
医疗器械(MDs)的使用,即葡萄糖传感器和胰岛素泵,在 1 型糖尿病(T1D)患者中已被证明对疾病控制有巨大优势。然而,这些 MDs 可能会引起不良反应,从而影响患者的依从性。本研究的目的是系统地回顾和分析评估 T1D 患者使用 MDs 相关的皮炎(包括与 MDs 相关的过敏性接触性皮炎[ACD])的患病率和发病率的研究,并比较参与欧洲环境和接触性皮炎研究组(EECDRG)的诊所的转诊途径和临床调查常规。我们对 PubMed、EMBASE、CINAHL 和 Cochrane 数据库进行了系统检索,以查找截至 2021 年 12 月报告 T1D 患者使用 MDs 的皮炎发病率和患病率的全文研究。我们使用纽卡斯尔-渥太华量表评估了研究质量。EECDRG 诊所进行的清单重点关注转诊途径、患者数量和诊断过程。在筛选出的 3145 篇摘要中,有 39 篇研究符合纳入标准。其中 16 项研究仅包括儿童数据,14 项研究为成人数据,9 项研究报告了儿童和成人的数据。参与者接触了广泛的设备。皮肤反应很少被明确说明。研究发现,不同中心的诊断过程和转诊途径存在差异。还需要进一步研究 T1D 个体与 MDs 相关的皮肤反应的患病率,特别是那些正确诊断皮肤反应的研究。由于目前 MDs 中的实际物质未被声明、未经通知就发生变化且商业上可获得的测试材料没有得到充分更新,因此正确的诊断被延迟或受到阻碍。在欧洲,应该使转诊常规更加标准化,以改善对 MDs 引起的疑似 ACD 患者的诊断程序。